公开(公告)号：US20240199695A1

公开(公告)日：2024-06-20

申请号：US18240295

申请日：2023-08-30

Applicant: TRANSFERT PLUS, S.E.C.

Inventor： Richard BÉLIVEAU ,  Borhane ANNABI ,  Michel DEMEULE ,  Alain LAROCQUE ,  Jean-Christophe CURRIE ,  Cyndia CHARFI

IPC: C07K7/08 ,  A61K31/337 ,  A61K47/64 ,  A61P35/00 ,  C07K1/06 ,  C07K14/00

CPC classification number: C07K7/08 ,  A61K31/337 ,  A61K47/64 ,  A61P35/00 ,  C07K1/061 ,  C07K14/001 ,  A61K38/00

Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula









(SEQ ID NO: 1)



X1X2X3X4X5GVX6AKAGVX7NX8FKSESY



(I)







(SEQ ID NO: 2)



(X9)nGVX10AKAGVX11NX12FKSESY



(II)







(SEQ ID NO: 3)



YKX13LRRX14APRWDX15PLRDPALRX16X17L



(III)







(SEQ ID NO: 4)



YKX18LRR(X19)nPLRDPALRX20X21L



(IV)







(SEQ ID NO: 5)



IKLSGGVQAKAGVINMDKSESM



(V)







(SEQ ID NO: 6)



IKLSGGVQAKAGVINMFKSESY



(VI)







(SEQ ID NO: 7)



IKLSGGVQAKAGVINMFKSESYK



(VII)







(SEQ ID NO: 8)



GVQAKAGVINMFKSESY



(VIII)







(SEQ ID NO: 9)



GVRAKAGVRNMFKSESY



(IX)







(SEQ ID NO: 10)



GVRAKAGVRN(Nle)FKSESY



(X)







(SEQ ID NO: 11)



YKSLRRKAPRWDAPLRDPALRQLL



(XI)







(SEQ ID NO: 12)



YKSLRRKAPRWDAYLRDPALRQLL



(XII)







(SEQ ID NO: 13)



YKSLRRKAPRWDAYLRDPALRPLL



(XIII)








wherein X1 to X21 and n can have various different values
and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

公开(公告)号：US20220356209A1

公开(公告)日：2022-11-10

申请号：US17239544

申请日：2021-04-23

Applicant: TRANSFERT PLUS, S.E.C.

Inventor： Richard BÉLIVEAU ,  Borhane ANNABI ,  Michel DEMEULE ,  Alain LAROCQUE ,  Jean-Christophe CURRIE ,  Cyndia CHARFI

IPC: C07K7/08 ,  A61K47/64 ,  A61P35/00 ,  A61K31/337 ,  C07K1/06 ,  C07K14/00

Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula X1X2X3X4X5GVX6AKAGVX7NX8FKSESY
(I)
(SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY
(II)
(SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L
(III)
(SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L
(IV)
(SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM
(V)
(SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY
(VI)
(SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK
(VII)
(SEQ ID NO: 7) GVQAKAGVINMFKSESY
(VIII)
(SEQ ID NO: 8) GVRAKAGVRNMFKSESY
(IX)
(SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY
(X)
(SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL
(XI)
(SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL
(XII)
(SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL
(XIII)
(SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.